908 Devices announced that GlaxoSmithKline has purchased an additional REBEL cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams. 908 Devices notes there are now 15 customers owning multiple REBEL devices, more than double from one year ago. In addition, all 20 of the top 20 pharmaceutical companies are now using the company's desktop devices, which include REBEL and ZipChip®, in their development process.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.17 USD | +11.57% |
|
+33.84% | -45.01% |
07-01 | 908 Devices Inc.(NasdaqGM:MASS) added to Russell Microcap Growth Index | CI |
07-01 | 908 Devices Inc.(NasdaqGM:MASS) added to Russell 3000E Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.01% | 191M | |
-27.34% | 16.26B | |
+13.44% | 1.78B | |
-15.91% | 1.41B | |
+37.40% | 1.29B | |
+5.96% | 836M | |
-30.52% | 807M | |
-38.05% | 708M | |
+27.36% | 611M | |
-26.54% | 590M |
- Stock Market
- Equities
- MASS Stock
- News 908 Devices Inc.
- 908 Devices Announces GlaxoSmithKline plc Purchases Fifth Rebel Cell Culture Media Analyzer